Intervention Insights, a Grand Rapids, Mich.-based healthcare information technology company, has closed a $7.2m Series B financing.
The round was co-led by Beringea and Chrysalis Ventures, with participation from Hopen Life Sciences, Michigan Accelerator Fund I and and other existing investors.
The company intends to use the funding to expand commercialization efforts for its OncInsights, which is designed to help community oncologists develop individualized patient treatment plans.
In conjunction with the funding, Beringea Managing Director Michael Gross and Chrysalis Managing Director Koleman Karleski have joined the company’s board of directors.
Founded in 2009 and led by CEO Jerry Callahan, Intervention Insights is based on Van Andel Research Institute’s bioinformatics platform that analyzes cancerous tissue, and generates a genomic picture of over 20,000 genes and corresponding molecular pathways that define a person’s cancer and the drugs that target them. The end result is a report, electronically delivered to oncologists to support them in making a treatment decision.